Arrowhead Pharmaceuticals (STU:HDP1) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HDP1 Arrowhead Pharmaceuticals Inc STU:HDP1
51 GF Score
Price €75.44
GF Value €53.12
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arrowhead Pharmaceuticals  (STU:HDP1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.78 11.44 8.27 6.13 10.59

Arrowhead Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 10.59 20.13 18.29 23.19

STU:HDP1 vs AXSM, MDGL, BMRN: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


STU:HDP1
51GF Score
Arrowhead Pharmaceuticals Inc STU:HDP1
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Arrowhead Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Arrowhead Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.818/333.9520*333.9520
=2.818

Current CPI (Jun. 2026) = 333.9520.

Arrowhead Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 1.221 241.428 1.689
201612 1.245 241.432 1.722
201703 1.174 243.801 1.608
201706 1.072 244.955 1.461
201709 0.913 246.819 1.235
201712 0.798 246.524 1.081
201803 1.058 249.554 1.416
201806 0.997 251.989 1.321
201809 0.928 252.439 1.228
201812 1.633 251.233 2.171
201903 1.881 254.202 2.471
201906 2.103 256.143 2.742
201909 2.325 256.759 3.024
201912 4.451 256.974 5.784
202003 4.395 258.115 5.686
202006 4.283 257.797 5.548
202009 3.830 260.280 4.914
202012 3.620 260.474 4.641
202103 3.598 264.877 4.536
202106 3.480 271.696 4.277
202109 3.331 274.310 4.055
202112 3.146 278.802 3.768
202203 3.885 287.504 4.513
202206 4.059 296.311 4.575
202209 3.799 296.808 4.274
202212 3.353 296.797 3.773
202303 3.905 301.836 4.321
202306 3.144 305.109 3.441
202309 2.369 307.789 2.570
202312 1.368 306.746 1.489
202403 3.586 312.332 3.834
202406 2.472 314.175 2.628
202409 1.343 315.301 1.422
202412 0.400 315.605 0.423
202503 4.578 319.799 4.781
202506 3.278 322.561 3.394
202509 2.926 324.800 3.008
202512 3.533 324.054 3.641
202603 3.778 330.213 3.821
202606 2.818 333.952 2.818

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Arrowhead Pharmaceuticals (STU:HDP1) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of €75.44 is trading 42% above its estimated GF Value™ of €53.12. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:HDP1:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €53.12 vs. price of €75.44 (42% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the STU:HDP1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
51GF Score

Get the complete analysis for STU:HDP1

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€75.44
Price
€53.12
GF Value